Asset Details
Do you wish to reserve the book?
Pathological mechanisms and treatment progression of Alzheimer’s disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pathological mechanisms and treatment progression of Alzheimer’s disease
Do you wish to request the book?
Pathological mechanisms and treatment progression of Alzheimer’s disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pathological mechanisms and treatment progression of Alzheimer’s disease
2025
Overview
Alzheimer's disease (AD) represents the most prevalent neurodegenerative disorder and leading cause of dementia worldwide, with its incidence rising dramatically in aging populations. This progressive disease is neuropathologically characterized by extracellular amyloid-β (Aβ) plaques, intracellular neurofibrillary tau tangles, and chronic neuroinflammation, leading to synaptic dysfunction and neuronal loss. Despite extensive research efforts, the complex and multifactorial nature of AD pathogenesis has prevented the development of truly disease-modifying therapies. Current therapeutic approaches, including recently approved anti-amyloid immunotherapies, demonstrate limited clinical efficacy and significant adverse effects, highlighting the need for alternative treatment strategies. This comprehensive review systematically evaluates recent advances in understanding AD pathophysiology, emphasizing the interplay between genetic risk factors (particularly APOE ε4), proteostasis imbalance, metabolic dysfunction, and neurovascular contributions. We critically analyze emerging diagnostic biomarkers, including novel neuroimaging techniques and cerebrospinal fluid/blood-based biomarkers, that enable earlier and more accurate detection. The review provides an in-depth assessment of both pharmacological interventions (such as tau-targeting therapies, anti-inflammatory agents, and neurotransmitter modulators) and non-pharmacological approaches (including lifestyle modifications and cognitive training). Special attention is given to personalized medicine strategies that account for disease heterogeneity and individual risk profiles. By synthesizing evidence from molecular studies, animal models, and clinical trials, we identify key challenges in therapeutic translation and propose future research directions. Our analysis underscores the importance of multimodal interventions targeting multiple pathological processes simultaneously, combined with early detection methods, to effectively combat this devastating disease. This review aims to provide researchers and clinicians with an updated framework for understanding AD pathogenesis and developing more effective treatment paradigms.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
